[
  {
    "ts": "2025-11-03T10:12:00+00:00",
    "headline": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
    "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
    "url": "https://finance.yahoo.com/news/united-states-multiple-myeloma-market-101200827.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3d33767a-80a0-39f6-b425-cf0864c74745",
      "content": {
        "id": "3d33767a-80a0-39f6-b425-cf0864c74745",
        "contentType": "STORY",
        "title": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
        "description": "",
        "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
        "pubDate": "2025-11-03T10:12:00Z",
        "displayTime": "2025-11-03T10:12:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/f0ad8df6a5e435cb735622670df8b993",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "U.S. Multiple Myeloma Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wCmcQt.cLkDgg20dBnjnRg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f0ad8df6a5e435cb735622670df8b993.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q92hRNIoyDOn3lP6EHRHpw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f0ad8df6a5e435cb735622670df8b993.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/united-states-multiple-myeloma-market-101200827.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/united-states-multiple-myeloma-market-101200827.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BAX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T09:02:00+00:00",
    "headline": "Sun Care Products Market Research Report 2025: An $18.91 Billion Market by 2030, Driven by Rising Demand for Clean & Natural Formulations, and AI Integration & Smart Beauty",
    "summary": "The global sun care products market is projected to grow at a CAGR of 4.77% between 2024 and 2030, driven by heightened skin health awareness and influencer marketing. Major players like Beiersdorf AG's NIVEA and Johnson & Johnson's Neutrogena are innovating, with products such as NIVEA's bespoke sun protection and Neutrogena's tie-up with John Cena for Ultra Sheer Mineral Sunscreen. North America leads the market, with over 35% share. The sun protection segment holds the largest share, while cr",
    "url": "https://finance.yahoo.com/news/sun-care-products-market-research-090200419.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "9e35251e-a622-3d27-bc4a-aa5a41778c40",
      "content": {
        "id": "9e35251e-a622-3d27-bc4a-aa5a41778c40",
        "contentType": "STORY",
        "title": "Sun Care Products Market Research Report 2025: An $18.91 Billion Market by 2030, Driven by Rising Demand for Clean & Natural Formulations, and AI Integration & Smart Beauty",
        "description": "",
        "summary": "The global sun care products market is projected to grow at a CAGR of 4.77% between 2024 and 2030, driven by heightened skin health awareness and influencer marketing. Major players like Beiersdorf AG's NIVEA and Johnson & Johnson's Neutrogena are innovating, with products such as NIVEA's bespoke sun protection and Neutrogena's tie-up with John Cena for Ultra Sheer Mineral Sunscreen. North America leads the market, with over 35% share. The sun protection segment holds the largest share, while cr",
        "pubDate": "2025-11-03T09:02:00Z",
        "displayTime": "2025-11-03T09:02:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/a8532ac1791e8a9989d157ac01917e2b",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Global Sun Care Products Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_XtOks6OC1KOvL5Absqmcw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a8532ac1791e8a9989d157ac01917e2b.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4o_HoXcemXb0AqSfB2whyA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a8532ac1791e8a9989d157ac01917e2b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sun-care-products-market-research-090200419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sun-care-products-market-research-090200419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BEI.DE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T21:54:59+00:00",
    "headline": "Kimberly-Clark Stock Takes Biggest One-Day Hit Since Black Monday",
    "summary": "Kimberly-Clark shares suffered their biggest one-day drop since the 1980s after the Huggies diapers maker agreed to buy Kenvue. Shares in the Tylenol maker leapt. At the close of trading:    Kimberly-Clark's stock fell 15% to $102.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-03-2025/card/kimberly-clark-stock-heads-for-biggest-one-day-drop-since-black-monday-RfalFwOjMGan1VoqOMHv?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "189cbb06-484d-3c9e-baf1-932ae22a0275",
      "content": {
        "id": "189cbb06-484d-3c9e-baf1-932ae22a0275",
        "contentType": "STORY",
        "title": "Kimberly-Clark Stock Takes Biggest One-Day Hit Since Black Monday",
        "description": "",
        "summary": "Kimberly-Clark shares suffered their biggest one-day drop since the 1980s after the Huggies diapers maker agreed to buy Kenvue. Shares in the Tylenol maker leapt. At the close of trading:    Kimberly-Clark's stock fell 15% to $102.",
        "pubDate": "2025-11-03T21:54:59Z",
        "displayTime": "2025-11-03T21:54:59Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/189cbb06-484d-3c9e-baf1-932ae22a0275/kimberly-clark-stock-takes.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-03-2025/card/kimberly-clark-stock-heads-for-biggest-one-day-drop-since-black-monday-RfalFwOjMGan1VoqOMHv?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T21:05:00+00:00",
    "headline": "BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors",
    "summary": "Global Aesthetics Leader Brings Deep Industry Expertise and Proven Track Record Driving Growth Across Health, Beauty, and Consumer Sectors Philippe Schaison Phillipe Schaison, PharmaD, to has been appointed to serve on The BeautyHealth Company Board of Directors. LONG BEACH, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced the appointment of global aesthetics leader, Philippe Schaison, PharmaD, to its Board of",
    "url": "https://finance.yahoo.com/news/beautyhealth-appoints-philippe-schaison-pharmad-210500252.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "fd139753-553c-3790-aaf8-cefdded99854",
      "content": {
        "id": "fd139753-553c-3790-aaf8-cefdded99854",
        "contentType": "STORY",
        "title": "BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors",
        "description": "",
        "summary": "Global Aesthetics Leader Brings Deep Industry Expertise and Proven Track Record Driving Growth Across Health, Beauty, and Consumer Sectors Philippe Schaison Phillipe Schaison, PharmaD, to has been appointed to serve on The BeautyHealth Company Board of Directors. LONG BEACH, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced the appointment of global aesthetics leader, Philippe Schaison, PharmaD, to its Board of",
        "pubDate": "2025-11-03T21:05:00Z",
        "displayTime": "2025-11-03T21:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/095d6de61316028aa77bc0f7834c1d3d",
          "originalWidth": 202,
          "originalHeight": 202,
          "caption": "Phillipe Schaison, PharmaD, to has been appointed to serve on The BeautyHealth Company Board of Directors.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TsyFE1wF9Zw3zVtf7SExbw--~B/aD0yMDI7dz0yMDI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/095d6de61316028aa77bc0f7834c1d3d.cf.webp",
              "width": 202,
              "height": 202,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BWZ2RcZ95aE4Xod7ey.skg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/095d6de61316028aa77bc0f7834c1d3d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/beautyhealth-appoints-philippe-schaison-pharmad-210500252.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/beautyhealth-appoints-philippe-schaison-pharmad-210500252.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SKIN"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "OR.PA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T20:45:00+00:00",
    "headline": "Kimberly-Clark to Buy Tylenol Maker Kenvue. Why the Stock Market Hates the Deal.",
    "summary": "Kimberly-Clark  is buying Tylenol maker  Kenvue  for nearly $50 billion.  The cash-and-stock transaction, announced Monday, values Kenvue at an enterprise value of about $48.7 billion, including debt.  Under the terms of the deal, Kenvue shareholders will receive $21.01 a share, based on Kenvue’s closing price of $14.37 on Friday.",
    "url": "https://www.barrons.com/articles/kmb-stock-price-kenvue-deal-kimberly-clark-tylenol-bcbd0ec3?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "88ce0b9d-2216-33bf-ae82-30bebe572b3a",
      "content": {
        "id": "88ce0b9d-2216-33bf-ae82-30bebe572b3a",
        "contentType": "STORY",
        "title": "Kimberly-Clark to Buy Tylenol Maker Kenvue. Why the Stock Market Hates the Deal.",
        "description": "",
        "summary": "Kimberly-Clark  is buying Tylenol maker  Kenvue  for nearly $50 billion.  The cash-and-stock transaction, announced Monday, values Kenvue at an enterprise value of about $48.7 billion, including debt.  Under the terms of the deal, Kenvue shareholders will receive $21.01 a share, based on Kenvue’s closing price of $14.37 on Friday.",
        "pubDate": "2025-11-03T20:45:00Z",
        "displayTime": "2025-11-03T20:45:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/88ce0b9d-2216-33bf-ae82-30bebe572b3a/kimberly-clark-to-buy-tylenol.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/4c5a1d62bedf8bbcce69ec4d131564a0",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4VjAtBmJXPcK9DM4yseugg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/4c5a1d62bedf8bbcce69ec4d131564a0.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4W54wQaQ4UUvA3TyVV3W6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/4c5a1d62bedf8bbcce69ec4d131564a0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/kmb-stock-price-kenvue-deal-kimberly-clark-tylenol-bcbd0ec3?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KDP"
            },
            {
              "symbol": "KHC"
            },
            {
              "symbol": "KMB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T20:41:54+00:00",
    "headline": "Dear Kenvue Stock Fans, Mark Your Calendars for November 6 Upcoming earnings",
    "summary": "Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.",
    "url": "https://www.barchart.com/story/news/35871317/dear-kenvue-stock-fans-mark-your-calendars-for-november-6-upcoming-earnings",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "c44e21ab-40e8-3226-aad4-09069b494b97",
      "content": {
        "id": "c44e21ab-40e8-3226-aad4-09069b494b97",
        "contentType": "STORY",
        "title": "Dear Kenvue Stock Fans, Mark Your Calendars for November 6 Upcoming earnings",
        "description": "",
        "summary": "Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.",
        "pubDate": "2025-11-03T20:41:54Z",
        "displayTime": "2025-11-03T20:41:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/c04640a4dce26cb2bdc9ad13c031bcce",
          "originalWidth": 1600,
          "originalHeight": 1200,
          "caption": "Packaged bottles of Tylenol on a store shelf by Kenishirotie via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_xL.dJjC3B_6HKzeAyfNA--~B/aD0xMjAwO3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/c04640a4dce26cb2bdc9ad13c031bcce.cf.webp",
              "width": 1600,
              "height": 1200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nH_BwLCECvtD0GKgwSgZDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/c04640a4dce26cb2bdc9ad13c031bcce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/35871317/dear-kenvue-stock-fans-mark-your-calendars-for-november-6-upcoming-earnings",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dear-kenvue-stock-fans-mark-204154526.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KMB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T20:00:02+00:00",
    "headline": "Is the End of the Line Near for Kenvue?",
    "summary": "The purchase of Kenvue by Kimberly-Clark announced Monday would mark the close of a short, rocky term of independence for the Tylenol maker, which was spun off from Johnson & Johnson in 2023.  Kenvue shares have been under pressure since President Trump’s warning that acetaminophen—the active ingredient in Tylenol—is a potential cause of autism.  Kenvue has called the claims baseless.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-03-2025/card/is-the-end-of-the-line-near-for-kenvue--tv1F0KP4CeZLpPhkEoHJ?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "402feb20-c97d-39f8-913a-b9601483bfd7",
      "content": {
        "id": "402feb20-c97d-39f8-913a-b9601483bfd7",
        "contentType": "STORY",
        "title": "Is the End of the Line Near for Kenvue?",
        "description": "",
        "summary": "The purchase of Kenvue by Kimberly-Clark announced Monday would mark the close of a short, rocky term of independence for the Tylenol maker, which was spun off from Johnson & Johnson in 2023.  Kenvue shares have been under pressure since President Trump’s warning that acetaminophen—the active ingredient in Tylenol—is a potential cause of autism.  Kenvue has called the claims baseless.",
        "pubDate": "2025-11-03T20:00:02Z",
        "displayTime": "2025-11-03T20:00:02Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/402feb20-c97d-39f8-913a-b9601483bfd7/is-the-end-of-the-line-near.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-03-2025/card/is-the-end-of-the-line-near-for-kenvue--tv1F0KP4CeZLpPhkEoHJ?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T19:23:08+00:00",
    "headline": "Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger",
    "summary": "Caroline Woods: Big brands and big money - Kimberly-Clark is buying Kenvue in a nearly $50 billion cash and stock deal. That would put Huggies, Kleenex, Band-Aid, Neutrogena and Tylenol all under one roof. It’s one of the biggest deals on Wall Street this year and a major move for Kimberly-Clark, ...",
    "url": "https://www.thestreet.com/video/kimberly-clark-to-buy-tylenol-maker-kenvue-in-massive-consumer-merger",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "a893961b-32f8-36f4-8d84-fd26d8e2f5e9",
      "content": {
        "id": "a893961b-32f8-36f4-8d84-fd26d8e2f5e9",
        "contentType": "STORY",
        "title": "Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger",
        "description": "",
        "summary": "Caroline Woods: Big brands and big money - Kimberly-Clark is buying Kenvue in a nearly $50 billion cash and stock deal. That would put Huggies, Kleenex, Band-Aid, Neutrogena and Tylenol all under one roof. It’s one of the biggest deals on Wall Street this year and a major move for Kimberly-Clark, ...",
        "pubDate": "2025-11-03T19:23:08Z",
        "displayTime": "2025-11-03T19:23:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/529ad3ef9f40b5211451373eab6a82f1",
          "originalWidth": 1181,
          "originalHeight": 800,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yVRrIIDm7_BCs79s6fMayQ--~B/aD04MDA7dz0xMTgxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/529ad3ef9f40b5211451373eab6a82f1.cf.webp",
              "width": 1181,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiVBB112DC6YbUzNoxMCTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/529ad3ef9f40b5211451373eab6a82f1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/video/kimberly-clark-to-buy-tylenol-maker-kenvue-in-massive-consumer-merger",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-buy-tylenol-maker-192308407.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KMB"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T19:13:16+00:00",
    "headline": "Kimberly-Clark bets $40 billion on Kenvue despite Tylenol controversy",
    "summary": "<body><p>STORY: :: Kimberly-Clark</p><p>Kimberly-Clarke is betting big on the maker of Tylenol, announcing it will acquire parent company Kenvue for more than $40 billion... marking the largest buyout ever among the U.S. consumer goods industry.</p><p>The historic deal comes after U.S. President Donald Trump made remarks about the painkiller at the White House in September, citing unproven claims linking Tylenol&nbsp;use during pregnancy to autism in children.</p><p>:: September 22, 2025</p><p>UPSOUND US PRESIDENT DONALD TRUMP: “Don't take Tylenol. Don't take it. If you just can't, I mean, fight like hell not to take it.\"</p><p>Shares of Tylenol-parent Kenvue - which also owns Band-Aid and Neutrogena - soared as much as 19% after the deal's announcement, while buyer Kimberly-Clark's shares tumbled about 14%.</p><p>:: File</p><p>Kenvue, which was spun off from Johnson & Johnson in 2023, has struggled for months with weak demand.</p><p>The company fired its CEO in July and said it was undergoing a strategic review of its assets.</p><p>Investor concern over Monday's merger announcement may stem in part from Kenvue's potential legal exposure to private lawsuits alleging it hid Tylenol's supposed link to autism in children.</p><p>U.S. sales of Tylenol fell 11% between September 20 and October 4 after Trump's remarks, according to a BNP Paribas analyst note last month.</p><p>:: Kimberly-Clark</p><p>But the merger does give Kimberly-Clark access to Kenvue's vast portfolio of brands - which also include Aveeno and Neutrogena - with the combined company expected to bring in annual revenues of roughly $32 billion.</p><p>The deal is expected to close in the second half of 2026.</p></body>",
    "url": "https://finance.yahoo.com/video/kimberly-clark-bets-40-billion-191316248.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "2b82d70d-dea3-33c8-8b8e-ddcab23cbfcf",
      "content": {
        "id": "2b82d70d-dea3-33c8-8b8e-ddcab23cbfcf",
        "contentType": "VIDEO",
        "title": "Kimberly-Clark bets $40 billion on Kenvue despite Tylenol controversy",
        "description": "<title><body><p>STORY: :: Kimberly-Clark</p><p>Kimberly-Clarke is betting big on the maker of Tylenol, announcing it will acquire parent company Kenvue for more than $40 billion... marking the largest buyout ever among the U.S. consumer goods industry.</p><p>The historic deal comes after U.S. President Donald Trump made remarks about the painkiller at the White House in September, citing unproven claims linking Tylenol use during pregnancy to autism in children.</p><p>:: September 22, 2025</p><p>UPSOUND US PRESIDENT DONALD TRUMP: “Don't take Tylenol. Don't take it. If you just can't, I mean, fight like hell not to take it.\"</p><p>Shares of Tylenol-parent Kenvue - which also owns Band-Aid and Neutrogena - soared as much as 19% after the deal's announcement, while buyer Kimberly-Clark's shares tumbled about 14%.</p><p>:: File</p><p>Kenvue, which was spun off from Johnson & Johnson in 2023, has struggled for months with weak demand.</p><p>The company fired its CEO in July and said it was undergoing a strategic review of its assets.</p><p>Investor concern over Monday's merger announcement may stem in part from Kenvue's potential legal exposure to private lawsuits alleging it hid Tylenol's supposed link to autism in children.</p><p>U.S. sales of Tylenol fell 11% between September 20 and October 4 after Trump's remarks, according to a BNP Paribas analyst note last month.</p><p>:: Kimberly-Clark</p><p>But the merger does give Kimberly-Clark access to Kenvue's vast portfolio of brands - which also include Aveeno and Neutrogena - with the combined company expected to bring in annual revenues of roughly $32 billion.</p><p>The deal is expected to close in the second half of 2026.</p></body></title>",
        "summary": "<body><p>STORY: :: Kimberly-Clark</p><p>Kimberly-Clarke is betting big on the maker of Tylenol, announcing it will acquire parent company Kenvue for more than $40 billion... marking the largest buyout ever among the U.S. consumer goods industry.</p><p>The historic deal comes after U.S. President Donald Trump made remarks about the painkiller at the White House in September, citing unproven claims linking Tylenol&nbsp;use during pregnancy to autism in children.</p><p>:: September 22, 2025</p><p>UPSOUND US PRESIDENT DONALD TRUMP: “Don't take Tylenol. Don't take it. If you just can't, I mean, fight like hell not to take it.\"</p><p>Shares of Tylenol-parent Kenvue - which also owns Band-Aid and Neutrogena - soared as much as 19% after the deal's announcement, while buyer Kimberly-Clark's shares tumbled about 14%.</p><p>:: File</p><p>Kenvue, which was spun off from Johnson & Johnson in 2023, has struggled for months with weak demand.</p><p>The company fired its CEO in July and said it was undergoing a strategic review of its assets.</p><p>Investor concern over Monday's merger announcement may stem in part from Kenvue's potential legal exposure to private lawsuits alleging it hid Tylenol's supposed link to autism in children.</p><p>U.S. sales of Tylenol fell 11% between September 20 and October 4 after Trump's remarks, according to a BNP Paribas analyst note last month.</p><p>:: Kimberly-Clark</p><p>But the merger does give Kimberly-Clark access to Kenvue's vast portfolio of brands - which also include Aveeno and Neutrogena - with the combined company expected to bring in annual revenues of roughly $32 billion.</p><p>The deal is expected to close in the second half of 2026.</p></body>",
        "pubDate": "2025-11-03T19:13:16Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/YgOM2erxQSPfrTVf1a7.Vw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d4a729ed-24b7-4417-8f70-0267983802e1/main/1280x720/53s719ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hcIBEJvJKXLu3E4DGKKCLg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d4a729ed-24b7-4417-8f70-0267983802e1/main/1280x720/53s719ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/c8J8AXBKrqFFgdditxvPHQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d4a729ed-24b7-4417-8f70-0267983802e1/main/1280x720/53s719ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/kimberly-clark-bets-40-billion-191316248.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/kimberly-clark-bets-40-billion-191316248.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T16:58:04+00:00",
    "headline": "Kimberly-Clark to Buy Kenvue in $48.7 Billion Deal",
    "summary": "Merger brings Huggies, Kleenex, and Tylenol under one roof",
    "url": "https://finance.yahoo.com/news/kimberly-clark-buy-kenvue-48-165804160.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "a47690f5-8113-3199-a63b-e2d38e0a2b7f",
      "content": {
        "id": "a47690f5-8113-3199-a63b-e2d38e0a2b7f",
        "contentType": "STORY",
        "title": "Kimberly-Clark to Buy Kenvue in $48.7 Billion Deal",
        "description": "",
        "summary": "Merger brings Huggies, Kleenex, and Tylenol under one roof",
        "pubDate": "2025-11-03T16:58:04Z",
        "displayTime": "2025-11-03T16:58:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/4130726cde7a7ee647f151f571fcfff6",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N.fGQykNhUxlTfTiHjLsKQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/4130726cde7a7ee647f151f571fcfff6.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5GWooKkPh90qV1KshR_0hA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/4130726cde7a7ee647f151f571fcfff6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-buy-kenvue-48-165804160.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-buy-kenvue-48-165804160.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KMB"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T16:33:00+00:00",
    "headline": "Tylenol trust crisis: Trump, RFK Jr. and Texas lawsuits slam Kenvue",
    "summary": "Kenvue, the company that makes Tylenol, is fighting on both the political and scientific fronts. The latest blow came from the U.S. Health Secretary, placing even more pressure on Kenvue stock, which has already lost 40% of its value in the last six months. Robert F. Kennedy Jr. recently made ...",
    "url": "https://www.thestreet.com/health/tylenol-trust-crisis-trump-rfk-jr-and-texas-lawsuits-slam-kenvue",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "7d1adaa7-1f5b-3db0-9abb-bf328fc8e684",
      "content": {
        "id": "7d1adaa7-1f5b-3db0-9abb-bf328fc8e684",
        "contentType": "STORY",
        "title": "Tylenol trust crisis: Trump, RFK Jr. and Texas lawsuits slam Kenvue",
        "description": "",
        "summary": "Kenvue, the company that makes Tylenol, is fighting on both the political and scientific fronts. The latest blow came from the U.S. Health Secretary, placing even more pressure on Kenvue stock, which has already lost 40% of its value in the last six months. Robert F. Kennedy Jr. recently made ...",
        "pubDate": "2025-11-03T16:33:00Z",
        "displayTime": "2025-11-03T16:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/2d0e0d55a9ba8b8633b159924f04f7b1",
          "originalWidth": 1200,
          "originalHeight": 674,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AO9DL1Tn0Awp2BJG2OyJ3A--~B/aD02NzQ7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/2d0e0d55a9ba8b8633b159924f04f7b1.cf.webp",
              "width": 1200,
              "height": 674,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JNDcHVH55dZBx.rBQS9znw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/2d0e0d55a9ba8b8633b159924f04f7b1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/health/tylenol-trust-crisis-trump-rfk-jr-and-texas-lawsuits-slam-kenvue",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tylenol-trust-crisis-trump-rfk-163300447.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "HLN.L"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ULVR.L"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "RKT.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T15:43:38+00:00",
    "headline": "Why Tylenol Maker Kenvue Stock Just Popped",
    "summary": "Kenvue's value isn't obvious -- but a merged Kenvue and Kimberly-Clark might be a buy.",
    "url": "https://www.fool.com/investing/2025/11/03/why-tylenol-maker-kenvue-stock-just-popped/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "290ab632-de8f-366d-b40d-08ef71a14689",
      "content": {
        "id": "290ab632-de8f-366d-b40d-08ef71a14689",
        "contentType": "STORY",
        "title": "Why Tylenol Maker Kenvue Stock Just Popped",
        "description": "",
        "summary": "Kenvue's value isn't obvious -- but a merged Kenvue and Kimberly-Clark might be a buy.",
        "pubDate": "2025-11-03T15:43:38Z",
        "displayTime": "2025-11-03T15:43:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ae87d7818d57038f1342dec2734c951f",
          "originalWidth": 1200,
          "originalHeight": 801,
          "caption": "Letters M and A surrounded by notebooks and computers.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u4P30MdxIfprq.aYCd.aCg--~B/aD04MDE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/ae87d7818d57038f1342dec2734c951f.cf.webp",
              "width": 1200,
              "height": 801,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IaFJHnVFHEK1_w80tQg1Ag--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ae87d7818d57038f1342dec2734c951f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/03/why-tylenol-maker-kenvue-stock-just-popped/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-tylenol-maker-kenvue-stock-154338068.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T14:16:32+00:00",
    "headline": "Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger",
    "summary": "Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny",
    "url": "https://finance.yahoo.com/news/kimberly-clark-buy-tylenol-maker-141632779.html",
    "source": "The Guardian",
    "provider": "yfinance",
    "raw": {
      "id": "d9857965-294f-3d68-8e73-8b73331789b0",
      "content": {
        "id": "d9857965-294f-3d68-8e73-8b73331789b0",
        "contentType": "STORY",
        "title": "Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger",
        "description": "",
        "summary": "Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny",
        "pubDate": "2025-11-03T14:16:32Z",
        "displayTime": "2025-11-03T14:16:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_guardian_765/d22535b761aec5f2c586aac6ac4a98f1",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.BzOcxLRkggdf.I.ITIlGA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_guardian_765/d22535b761aec5f2c586aac6ac4a98f1.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CyE7MqPA4srIm6PurDsduA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_guardian_765/d22535b761aec5f2c586aac6ac4a98f1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Guardian",
          "url": "https://www.theguardian.com/international"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-buy-tylenol-maker-141632779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-buy-tylenol-maker-141632779.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KMB"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T13:19:57+00:00",
    "headline": "Kimberly-Clark buys Tylenol maker Kenvue for more than $48 billion",
    "summary": "The deal will create a new consumer health giant, bringing Kenvue under the wing of the maker of Kleenex tissues and Huggies diapers",
    "url": "https://qz.com/kimberly-clark-buys-tylenol-kenvue",
    "source": "Quartz",
    "provider": "yfinance",
    "raw": {
      "id": "7b3470c4-020d-3467-8759-23c34ab07784",
      "content": {
        "id": "7b3470c4-020d-3467-8759-23c34ab07784",
        "contentType": "STORY",
        "title": "Kimberly-Clark buys Tylenol maker Kenvue for more than $48 billion",
        "description": "",
        "summary": "The deal will create a new consumer health giant, bringing Kenvue under the wing of the maker of Kleenex tissues and Huggies diapers",
        "pubDate": "2025-11-03T13:19:57Z",
        "displayTime": "2025-11-03T13:19:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/quartz_855/5939bd0573afbc66c81ba246ce3a1ff9",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Vfgs6W2keli9l8ZjgXZRRg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/quartz_855/5939bd0573afbc66c81ba246ce3a1ff9.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/egoZBUUj1t9UFa96qXyIcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/quartz_855/5939bd0573afbc66c81ba246ce3a1ff9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Quartz",
          "url": "https://qz.com/"
        },
        "canonicalUrl": {
          "url": "https://qz.com/kimberly-clark-buys-tylenol-kenvue",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-buys-tylenol-maker-131957033.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T12:21:41+00:00",
    "headline": "Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal",
    "summary": "Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.  Shareholders of Kimberly-Clark will own about 54% of the combined company.  Kenvue shareholders will own about 46% in what is one of the largest corporate takeovers this year.",
    "url": "https://finance.yahoo.com/news/kimberly-clark-buying-tylenol-maker-122141133.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "39e1ad68-f6e3-3208-9f2b-4bf27b411b50",
      "content": {
        "id": "39e1ad68-f6e3-3208-9f2b-4bf27b411b50",
        "contentType": "STORY",
        "title": "Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal",
        "description": "",
        "summary": "Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.  Shareholders of Kimberly-Clark will own about 54% of the combined company.  Kenvue shareholders will own about 46% in what is one of the largest corporate takeovers this year.",
        "pubDate": "2025-11-03T12:21:41Z",
        "displayTime": "2025-11-03T12:21:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ap_finance_articles_694/4c917230d65aeecb6383be6c71710cdc",
          "originalWidth": 5164,
          "originalHeight": 3443,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uanQbYiHJ3OdLkVMKIxPow--~B/aD0zNDQzO3c9NTE2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/ap_finance_articles_694/4c917230d65aeecb6383be6c71710cdc.cf.webp",
              "width": 5164,
              "height": 3443,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mVdHF9rNmpc5NYNyWj6EXw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ap_finance_articles_694/4c917230d65aeecb6383be6c71710cdc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-buying-tylenol-maker-122141133.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-buying-tylenol-maker-122141133.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KMB"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T12:00:00+00:00",
    "headline": "Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors",
    "summary": "-Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025-HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platf",
    "url": "https://finance.yahoo.com/news/benitec-biopharma-announces-appointment-sharon-120000744.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c63a01cc-e4e5-30f5-88fd-ab297cc22cbb",
      "content": {
        "id": "c63a01cc-e4e5-30f5-88fd-ab297cc22cbb",
        "contentType": "STORY",
        "title": "Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors",
        "description": "",
        "summary": "-Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025-HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platf",
        "pubDate": "2025-11-03T12:00:00Z",
        "displayTime": "2025-11-03T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/6420004cb8cbc8cbf0c4b9dec039e88f",
          "originalWidth": 803,
          "originalHeight": 254,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WFixuy_mK2gzmfv_0MoFxw--~B/aD0yNTQ7dz04MDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6420004cb8cbc8cbf0c4b9dec039e88f.cf.webp",
              "width": 803,
              "height": 254,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4Hod2OhSb3o23mSOSVyH1Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6420004cb8cbc8cbf0c4b9dec039e88f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/benitec-biopharma-announces-appointment-sharon-120000744.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/benitec-biopharma-announces-appointment-sharon-120000744.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BNTC"
            },
            {
              "symbol": "ITCI"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T11:47:51+00:00",
    "headline": "Kimberly-Clark to Acquire Kenvue",
    "summary": "The deal is valued at $48.7 billion.",
    "url": "https://wwd.com/beauty-industry-news/beauty-features/kimberly-clark-acquire-kenvue-1238333479/",
    "source": "WWD",
    "provider": "yfinance",
    "raw": {
      "id": "28ac3a56-60f1-3ac3-a54b-957e181d62b2",
      "content": {
        "id": "28ac3a56-60f1-3ac3-a54b-957e181d62b2",
        "contentType": "STORY",
        "title": "Kimberly-Clark to Acquire Kenvue",
        "description": "",
        "summary": "The deal is valued at $48.7 billion.",
        "pubDate": "2025-11-03T11:47:51Z",
        "displayTime": "2025-11-03T11:47:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wwd_409/4553a6a733f974e7f8430b40ad808537",
          "originalWidth": 8192,
          "originalHeight": 5464,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2qm43qg9rQYr3FJ33v0.ZA--~B/aD01NDY0O3c9ODE5MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/wwd_409/4553a6a733f974e7f8430b40ad808537.cf.webp",
              "width": 8192,
              "height": 5464,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fdTwVvFjQZR7CBqKH8jItA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wwd_409/4553a6a733f974e7f8430b40ad808537.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "WWD",
          "url": "https://wwd.com/"
        },
        "canonicalUrl": {
          "url": "https://wwd.com/beauty-industry-news/beauty-features/kimberly-clark-acquire-kenvue-1238333479/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-acquire-kenvue-114751486.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T11:47:00+00:00",
    "headline": "Japan Non-Invasive Aesthetic Treatment Market Analysis and Outlook 2025-2033 with City-Level Breakdowns by Procedure, Gender and End User",
    "summary": "Growth is driven by a rising demand for minimally invasive solutions, advances in technology, and increased beauty consciousness. The aging population and a booming MedSpa culture also contribute to market expansion. However, challenges include high costs and regulatory barriers. Major players like Johnson & Johnson and Galderma are key contributors to this evolving sector. Japanese Non-Invasive Aesthetic Treatment Market Japanese Non-Invasive Aesthetic Treatment Market Dublin, Nov. 03, 2025 (GL",
    "url": "https://finance.yahoo.com/news/japan-non-invasive-aesthetic-treatment-114700319.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "fca81c8a-3c67-3fce-a76f-9ae4ed64f6df",
      "content": {
        "id": "fca81c8a-3c67-3fce-a76f-9ae4ed64f6df",
        "contentType": "STORY",
        "title": "Japan Non-Invasive Aesthetic Treatment Market Analysis and Outlook 2025-2033 with City-Level Breakdowns by Procedure, Gender and End User",
        "description": "",
        "summary": "Growth is driven by a rising demand for minimally invasive solutions, advances in technology, and increased beauty consciousness. The aging population and a booming MedSpa culture also contribute to market expansion. However, challenges include high costs and regulatory barriers. Major players like Johnson & Johnson and Galderma are key contributors to this evolving sector. Japanese Non-Invasive Aesthetic Treatment Market Japanese Non-Invasive Aesthetic Treatment Market Dublin, Nov. 03, 2025 (GL",
        "pubDate": "2025-11-03T11:47:00Z",
        "displayTime": "2025-11-03T11:47:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/4797f974a2de9403c6d02d114c28f0c6",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Japanese Non-Invasive Aesthetic Treatment Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.3VKY1JmGXziKudWy1POOg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4797f974a2de9403c6d02d114c28f0c6.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rX7Iy7QUQgv56PrzKaB77A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4797f974a2de9403c6d02d114c28f0c6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/japan-non-invasive-aesthetic-treatment-114700319.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/japan-non-invasive-aesthetic-treatment-114700319.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T11:15:00+00:00",
    "headline": "Will President Trump's Tylenol Claims Hurt These 2 Leading Pharmaceutical Stocks?",
    "summary": "Even though Kenvue's stock was already in a tailspin before the FDA warned pregnant woman that Tylenol posed a health risk, there are still some lingering impacts to consider.",
    "url": "https://www.fool.com/investing/2025/11/03/will-president-trumps-tylenol-claims-hurt-these-2/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "c8dab48a-2778-3162-b9e9-8eb03ffc1f0b",
      "content": {
        "id": "c8dab48a-2778-3162-b9e9-8eb03ffc1f0b",
        "contentType": "STORY",
        "title": "Will President Trump's Tylenol Claims Hurt These 2 Leading Pharmaceutical Stocks?",
        "description": "",
        "summary": "Even though Kenvue's stock was already in a tailspin before the FDA warned pregnant woman that Tylenol posed a health risk, there are still some lingering impacts to consider.",
        "pubDate": "2025-11-03T11:15:00Z",
        "displayTime": "2025-11-03T11:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3a9283aca08041034a9f974fbd5e23e0",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A broken piggy bank.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A.P0aQDfz5aLyq4PNo4q0g--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/3a9283aca08041034a9f974fbd5e23e0.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jShLhXGXOZ1tI12QOcks5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3a9283aca08041034a9f974fbd5e23e0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/03/will-president-trumps-tylenol-claims-hurt-these-2/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/president-trumps-tylenol-claims-hurt-111500816.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T09:31:38+00:00",
    "headline": "Johnson & Johnson Stock: Is Wall Street Bullish or Bearish?",
    "summary": "Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.",
    "url": "https://www.barchart.com/story/news/35857637/johnson-johnson-stock-is-wall-street-bullish-or-bearish",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "36482b2a-75e4-3ffd-bfee-18a338733273",
      "content": {
        "id": "36482b2a-75e4-3ffd-bfee-18a338733273",
        "contentType": "STORY",
        "title": "Johnson & Johnson Stock: Is Wall Street Bullish or Bearish?",
        "description": "",
        "summary": "Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.",
        "pubDate": "2025-11-03T09:31:38Z",
        "displayTime": "2025-11-03T09:31:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/f73d6052e1efac84ccd7c35313ef07a4",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Johnson & Johnson logo on phone-by Allmy via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5oSeDG3zEpCshvbzOx7MbA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/f73d6052e1efac84ccd7c35313ef07a4.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q_c8kmgvp1L_C_KJXyuqhg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/f73d6052e1efac84ccd7c35313ef07a4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/35857637/johnson-johnson-stock-is-wall-street-bullish-or-bearish",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-stock-wall-street-093138584.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T13:27:19+00:00",
    "headline": "Tylenol maker Kenvue misses sales estimates amid Kimberly-Clark's $48.7-billion deal",
    "summary": "(Reuters) -Kenvue missed Wall Street estimates for third-quarter sales on Monday, while it also announced its acquisition by Kimberly-Clark for about $48.7 billion.",
    "url": "https://ca.finance.yahoo.com/news/tylenol-maker-kenvue-misses-sales-132719150.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "0f23ec78-6395-3dc9-8e13-1d8b7a755c72",
      "content": {
        "id": "0f23ec78-6395-3dc9-8e13-1d8b7a755c72",
        "contentType": "STORY",
        "title": "Tylenol maker Kenvue misses sales estimates amid Kimberly-Clark's $48.7-billion deal",
        "description": "",
        "summary": "(Reuters) -Kenvue missed Wall Street estimates for third-quarter sales on Monday, while it also announced its acquisition by Kimberly-Clark for about $48.7 billion.",
        "pubDate": "2025-11-03T13:27:19Z",
        "displayTime": "2025-11-03T13:27:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/0bf8a80fcd477e80c287df48b713675c",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "The company logo for Kenvue Inc. Johnson & Johnson's consumer-health business, is displayed on during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023.  REUTERS/Brendan McDermid",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0yr0WvJZsmFQrcEL57ICzg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/0bf8a80fcd477e80c287df48b713675c.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I44vk.y1ZhO1Vwu5ixONTw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/0bf8a80fcd477e80c287df48b713675c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/tylenol-maker-kenvue-misses-sales-132719150.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tylenol-maker-kenvue-misses-sales-132719150.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]